CMS Welcomes SCD-HeFT Data, Awaits COMPANION Study For ICD Review
This article was originally published in The Gray Sheet
Executive Summary
CMS plans to integrate Guidant's COMPANION study findings with recently released data from the SCD-HeFT trial to make a decision on whether to redefine the patient population eligible for ICD coverage
You may also be interested in...
CMS Drops QRS Restriction From Defibrillator Policy, Requires Registry
Guidant will lobby CMS to reconsider the COMPANION CRT-D trial data before finalizing a new implantable cardioverter defibrillator coverage policy
CMS Drops QRS Restriction From Defibrillator Policy, Requires Registry
Guidant will lobby CMS to reconsider the COMPANION CRT-D trial data before finalizing a new implantable cardioverter defibrillator coverage policy
Guidant CRT-D Non-Ischemic Label Expansion Endorsed By FDA Panel
Guidant cardiac resynchronization therapy defibrillators reduce heart failure mortality and symptoms for both ischemic and non-ischemic patients but may not prevent hospitalizations, according to FDA's Circulatory System Devices Panel